TXG Earnings & Financial Statements
10x Genomics, Inc.
$73.10
+$1.31(+1.82%)
63
Overall
60
Value
66
Tech
65
Quality
Market Cap
$9.52B
Volume
4.14M
52W Range
$11.16 - $102.81
Target Price
$68.24
TXG earnings and financial statements: 10x Genomics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
TXG Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $642.82M | $610.78M | $618.73M | $516.41M | $490.49M |
| Cost of revenue | $198.94M | $196.30M | $209.41M | $120.39M | $74.09M |
| Operating income | -$60.98M | -$194.56M | -$265.33M | -$167.94M | -$52.25M |
| EBITDA | $3.91M | -$133.99M | -$205.11M | -$128.49M | -$24.59M |
| Net income | -$43.54M | -$182.63M | -$255.10M | -$166.00M | -$58.22M |
| EPS (diluted) | $-0.35 | $-1.52 | $-2.18 | $-1.46 | $-0.53 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.04B | $918.64M | $965.14M | $1.03B | $1.02B |
| Total liabilities | $245.04M | $208.50M | $224.10M | $223.24M | $201.26M |
| Shareholders’ equity | $796.33M | $710.13M | $741.04M | $805.74M | $817.57M |
| Cash and equivalents | $473.97M | $344.07M | $359.28M | $219.75M | $587.45M |
| Long-term debt | $73.38M | $73.33M | $83.85M | $86.14M | $76.85M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $136.05M | $6.66M | -$15.20M | -$33.61M | -$21.37M |
| Capital expenditure | -$5.93M | -$13.39M | -$49.52M | -$131.66M | -$101.28M |
| Free cash flow | $130.12M | -$6.73M | -$64.72M | -$165.27M | -$122.65M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TXG | $73.10 | +1.8% | 4.14M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |